Page 21234..1020..»

Buckeye butterflies get their color from their scales – Massive Science

By daniellenierenberg

To Read More: Buckeye butterflies get their color from their scales – Massive Science
categoriaSkin Stem Cells commentoComments Off on Buckeye butterflies get their color from their scales – Massive Science | dataJune 3rd, 2020
Read All

CSL Behring and Seattle Children’s Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases | DNA RNA and Cells |…

By daniellenierenberg

DetailsCategory: DNA RNA and CellsPublished on Wednesday, 03 June 2020 09:39Hits: 306

Initially, the alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia (XLA)

SEATTLE, WA and KING of PRUSSIA, PA, USA I June 2, 2020 I Seattle Children's Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL Behring announced a strategic alliance to develop stem cell gene therapies for primary immunodeficiency diseases.

Initially, the alliance will focus on the development of treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome and X-linked Agammaglobulinemia. These are two of more than 400 identified primary immunodeficiency diseases in which a part of the body's immune system is missing or functions improperly.

"CSL Behring will collaborate with Seattle Children's experts to apply our novel gene therapy technology to their research pipeline, with an aim to address unmet needs for people living with certain rare primary immunodeficiency diseases," said Bill Mezzanotte, MD, Executive Vice President, Head of Research and Development for CSL Behring. "Expanding our gene therapy portfolio into an area of immunology well known to CSL exemplifies how we are strategically growing our capabilities in this strategic scientific platform and are collaborating with world class institutions to access innovation with the potential to vastly improve patients' lives."

"Stem cell gene therapies that correct the genetic abnormality driving a child's disease will transform the therapeutic options for children with Wiskott-Aldrich Syndrome, X-Linked Agammaglobulinemia and other immunodeficiency diseases,"said David J. Rawlings, MD, director of the Center for Immunity and Immunotherapies and division chief of immunology at Seattle Children's, and a professor of pediatrics and immunology at the University of Washington School of Medicine."The collaboration with CSL Behring supports our longstanding research programs for pediatric immunodeficiency diseases and will accelerate this research toward clinical trials, helping get these innovations to the children who need them."

CSL Behring researchers, working with researchers from Seattle Children's Research Institute, will investigate applying the proprietary platform technologies, Select+ and Cytegrity, to several pre-clinical gene therapy programs. These technologies, which have broad applications in ex vivo stem cell gene therapy, are designed to address some of the major challenges associated with the commercialization of stem cell therapy, including the ability to manufacture consistent, high-quality products, and to improve engraftment, efficacy and tolerability.

Wiskott-Aldrich Syndrome (WAS) has an estimated incidence between one and 10 cases per million males worldwide, according to the National Institutes of Health. WAS patients' immune systems function abnormally, making them susceptible to infections. They also experience eczema, autoimmunity and difficulty forming blood clots, leaving them vulnerable to life threatening bleeding complications. Today the only knowncurefor WAS is a stem cell transplant, if a suitable donor can be found.

X-linked Agammaglobulinemia (XLA) is another rare primary immunodeficiency in which patients have low levels of immunoglobulins (also known as antibodies), which are key proteins made by the immune system to help fight infections. Like WAS, XLA affects males almost exclusively, although females can be genetic carriers of the condition. While no cure exists for XLA, the goal of treatment is to boost the immune system by replacing missing antibodies and preventing or aggressively treating infections that occur, according to the Immune Deficiency Foundation.

About Seattle Children's

Seattle Children's mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children's Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.

Ranked as one of the top children's hospitals in the country by U.S. News & World Report, Seattle Children's serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho the largest region of any children's hospital in the country. As one of the nation's top five pediatric research centers, Seattle Children's Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children's Hospital and Research Foundation works with the Seattle Children's Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research. Join Seattle Children's bold initiative It Starts With Yes: The Campaign for Seattle Children's to transform children's health for generations to come.

For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 26,000 people, and delivers its life-saving therapies to people in more than 70 countries. For more information, visit http://www.cslbehring.com and for inspiring stories about the promise of biotechnology, visit Vita http://www.cslbehring.com/Vita.

SOURCE: CSL Behring

See more here:
CSL Behring and Seattle Children's Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases | DNA RNA and Cells |...

To Read More: CSL Behring and Seattle Children’s Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases | DNA RNA and Cells |…
categoriaCardiac Stem Cells commentoComments Off on CSL Behring and Seattle Children’s Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases | DNA RNA and Cells |… | dataJune 3rd, 2020
Read All

OpGen Expands Partnership with New York State Department of Health and IDC to Detect Antimicrobial-Resistant Infections – GuruFocus.com

By daniellenierenberg

GAITHERSBURG, Md., June 03, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that its strategic collaboration with the New York State Department of Health (DOH) to develop a state-of-the-art solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide is entering into its second year expansion phase. Having successfully achieved all of the milestones of the first year pilot phase for the development of an infectious disease digital health and precision medicine platform that connects healthcare institutions to DOH and uses genomic microbiology for statewide surveillance and control of antimicrobial resistance, OpGen will continue to work together with DOHs Wadsworth Center, participating healthcare systems, and collaborators such as Infectious Disease Connect, Inc. (IDC), which recently combined with ILM Health Solutions, to expand the reach of the platform, increase the volume of testing, and enhance data collection.

The DOH, OpGen, IDC and all stakeholders will continue to work collaboratively to demonstrate that a sustainable, flexible infectious diseases reporting, tracking and surveillance tool for antimicrobial resistance can be applied across New York State. The second-year expansion phase will build on the successes and experience of the first year pilot phase while focusing on accomplishing the goal of this visionary effort to improve patient outcomes and save healthcare dollars by integrating real-time epidemiologic surveillance with rapid delivery of antibiotic resistance results to care-givers via web-based and mobile platforms. OpGen is providing its Acuitas AMR Gene Panel for rapid detection of multidrug-resistant bacterial pathogens along with its Acuitas Lighthouse Software for high resolution pathogen tracking. The second year contract includes a quarterly retainer-based project fee as well as volume-dependent per test fees for a total contract value of up to $450,000 to OpGen.

We are excited and grateful that despite the continued threat of the COVID-19 pandemic which has hit New York State harder than any other place in the world, the Department of Health of New York State and the Wadsworth Center continue to work with us and have expanded their partnership for a second year, adding up to 3,500 AMR Gene Panel tests to be run, commented Oliver Schacht, CEO of OpGen. The quick spread of antimicrobial resistant superbugs across our healthcare systems is lurking below the current medical crisis. We anticipate that with our innovative diagnostic solutions we will be able to proactively identify such pathogens leading to early intervention and lifesaving treatment. A further project expansion of this nature may include the exploration of ways to achieve SARS-CoV-2 tracking.

Paul Edwards, Chief Strategy Officer at IDC commented, Our collaboration with OpGen allows us to not only identify bacteria and antimicrobial resistance down to the gene level but also to identify new or significant results versus phenotypic results alone. This molecular epidemiology capability in turn is critical in order to rapidly identify new clusters and outbreaks which otherwise would be missed and could potentially lead to outbreaks of hospital superbugs.

The precision medicine solutions provided by OpGen to accomplish the project goals are:

Wadsworth Center Director Dr. Jill Taylor said,"Under Governor Cuomo's leadership, New York State continues to lead the nation in addressing the threat of antimicrobial resistance. Working with our private-sector partners, the Wadsworth Center is able to further advance our mission to improve the public health of all New Yorkers.

About Antimicrobial-resistant InfectionsThe Centers for Disease Control and Prevention estimates that annually in the United States we face 2.8 million infections with 35,000 deaths and $49 billion in lost productivity all attributable to antibiotic resistant infections. Among the infectious diseases the parties are working to address are carbapenem-resistant Enterobacteriaceae (CRE) bacteria; they are untreatable and hard-to-treat infections on the rise among patients in medical facilities. CREs have become resistant to all or nearly all the antibiotics we have today. Almost half of hospital patients who get bloodstream infections from CRE bacteria die from the infection. The CDC has classified CREs as one of three urgent threats to the public health.

About Wadsworth Center LaboratoriesThe Wadsworth Center laboratories stand at the forefront of biomedical and environmental sciences and their interplay. The Center serves a vital role in the New York State Department of Healths efforts to protect and promote the health of New Yorks citizens. Building on more than a century of excellence as the states public health laboratory, the Center continues as a premier biomedical institute that merges clinical and environmental testing with fundamental, applied and translational research. Today, Wadsworth Center scientists use both classical and contemporary approaches to study environmental and biological questions related to human health and disease. They develop advanced methods to identify microbial or chemical threats; study drug resistance, emerging infections, and environmental exposures; manage the countrys most comprehensive diagnostic and environmental testing laboratory permit program; oversee extramural research programs on stem cells, breast cancer and spinal cord injury; and train the next generation of scientists through undergraduate, graduate, postdoctoral and visiting scientist programs.

About OpGen Inc.

OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGens product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit http://www.opgen.com.

Forward-Looking Statements

This press release includes statements regarding OpGens second year project phase with the New York State DOH. These statements and other statements regarding OpGens future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, our ability to successfully complete the second phase of the project with the New York State DOH, the rate of adoption of our products and services by hospitals and other healthcare providers, the realization of expected benefits of our business combination transaction with Curetis GmbH, the success of our commercialization efforts, the impact of COVID-19 on the Companys operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen:Oliver SchachtPresident and CEO[emailprotected]

OpGen Press Contact:Matthew BretziusFischTank PR[emailprotected]

OpGen Investor Contact:Joe GreenEdison Group[emailprotected]

View original post here:
OpGen Expands Partnership with New York State Department of Health and IDC to Detect Antimicrobial-Resistant Infections - GuruFocus.com

To Read More: OpGen Expands Partnership with New York State Department of Health and IDC to Detect Antimicrobial-Resistant Infections – GuruFocus.com
categoriaSpinal Cord Stem Cells commentoComments Off on OpGen Expands Partnership with New York State Department of Health and IDC to Detect Antimicrobial-Resistant Infections – GuruFocus.com | dataJune 3rd, 2020
Read All

Donating Stem Cells and Bone Marrow

By daniellenierenberg

People usually volunteer to donate stem cells for an allogeneic transplant either because they have a loved one or friend who needs a match or because they want to help people. Some people give their stem cells so they can get them back later if they need an autologous transplant.

People who want to donate stem cells or join a volunteer registry can speak with a health care provider or contact the National Marrow Donor Program to find the nearest donor center. Potential donors are asked questions to make sure they are healthy enough to donate and dont pose a risk of infection to the recipient. For more information about donor eligibility guidelines, contact Be the Match or the donor center in your area.

Be the Match (formerly the National Marrow Donor Program)Toll-free number: 1-800-MARROW-2 (1-800-627-7692)Website: http://www.bethematch.org

A simple blood test is done to learn the potential donors HLA type. There may be a one-time, tax-deductible fee of about $75 to $100 for this test. People who join a volunteer donor registry will most likely have their tissue type kept on file until they reach age 60.

Pregnant women who want to donate their babys cord blood should make arrangements for it early in the pregnancy, at least before the third trimester. Donation is safe, free, and does not affect the birth process.

If a possible stem cell donor is found to be a good match for a recipient, steps are taken to teach the donor about the transplant process and make sure he or she is making an informed decision. If a person decides to donate, a consent form must be signed after the risks of donating are fully discussed. The donor is not pressured to take part. Its always a choice.

If a person decides to donate, a medical exam and blood tests will be done to make sure the donor is in good health.

Stem cells may be collected from these 3 different sources:

Each method of collection is explained here.

This process is often called bone marrow harvest. Its done in an operating room, while the donor is under general anesthesia (given medicine to put them into a deep sleep so they dont feel pain). The marrow cells are taken from the back of the pelvic (hip) bone. The donor lies face down, and a large needle is put through the skin and into the back of the hip bone. Its pushed through the bone to the center and the thick, liquid marrow is pulled out through the needle. This is repeated several times until enough marrow has been taken out (harvested). The amount taken depends on the donors weight. Often, about 10% of the donors marrow, or about 2 pints, are collected. This takes about 1 to 2 hours. The body will replace these cells within 4 to 6 weeks. If blood was taken from the donor before the marrow donation, its often given back to the donor at this time.

After the bone marrow is harvested, the donor is taken to the recovery room while the anesthesia wears off. The donor may then be taken to a hospital room and watched until fully alert and able to eat and drink. In most cases, the donor is able to leave the hospital within a few hours or by the next morning.

The donor may have soreness, bruising, and aching at the back of the hips and lower back for a few days. Over-the-counter pain medications or nonsteroidal anti-inflammatory drugs are helpful. Some people may feel tired or weak, and have trouble walking for a few days. The donor might be told to take iron supplements until the number of red blood cells returns to normal. Most donors get back to their usual activities in 2 to 3 days. But it could take 2 or 3 weeks before they feel completely back to normal.

There arent many risks for donors and serious complications are rare. But bone marrow donation is a surgical procedure. Rare complications could include anesthesia reactions, infection, nerve or muscle damage, transfusion reactions (if a blood transfusion of someone elses blood is needed this doesnt happen if you get your own blood), or injury at the needle insertion sites. Problems such as sore throat or nausea may be caused by anesthesia.

Allogeneic stem cell donors do not have to pay for the harvesting because the recipients insurance company usually covers the cost. Even so, be sure to ask about insurance coverage before you decide to have the bone marrow harvest done.

Once the cells are collected, they are filtered through fine mesh screens. This prevents bone or fat particles from being given to the recipient. For an allogeneic or syngeneic transplant, the cells may be given to the recipient through a vein soon after they are harvested. Sometimes theyre frozen, for example, if the donor lives far away from the recipient.

For several days before starting the donation process, the donor is given a daily injection (shot) of a drug that causes the bone marrow to make and release a lot of stem cells into the blood. Filgrastim can cause some side effects, the most common being bone pain and headaches. These may be helped by over-the-counter pain medications or nonsteroidal anti-inflammatory drugs. Nausea, sleeping problems, low-grade (mild) fevers, and tiredness are other possible effects. These go away once the injections are finished and collection is completed.

After the shots, blood is removed through a catheter (a thin, flexible plastic tube) thats put in a large vein in the arm. Its then cycled through a machine that separates the stem cells from the other blood cells. The stem cells are kept while the rest of the blood is returned to the donor, often through the same catheter. (In some cases, a catheter may be put in each arm one takes out blood and the other puts it back.) This process is called apheresis. It takes about 2 to 4 hours and is done as an outpatient procedure. Often the process needs to be repeated daily for a few days, until enough stem cells have been collected.

Possible side effects of the catheter can include trouble placing the catheter in the vein, blockage of the catheter, or infection of the catheter or at the area where it enters the vein. Blood clots are another possible side effect. During the apheresis procedure, donors may have problems caused by low calcium levels from the anti-coagulant drug used to keep the blood from clotting in the machine. These can include feeling lightheaded or tingly, and having chills or muscle cramps. These go away after donation is complete, but may be treated by giving the donor calcium supplements.

The process of donating cells for yourself (autologous stem cell donation) is pretty much the same as when someone donates them for someone else (allogeneic donation). Its just that in autologous stem cell donation the donor is also the recipient, giving stem cells for his or her own use later on. For some people, there are a few differences. For instance, sometimes chemotherapy (chemo) is given before the growth factor drug is used to tell the body to make stem cells. Also, sometimes it can be hard to get enough stem cells from a person with cancer. Even after several days of apheresis, there may not be enough for the transplant. This is more likely to be a problem if the patient has had certain kinds of chemo in the past, or if they have an illness that affects their bone marrow.

Cord blood is the blood thats left in the placenta and umbilical cord after a baby is born. Collecting it does not pose any health risk to the infant or the mother. Cord blood transplants use blood that would otherwise be thrown away. After the umbilical cord is clamped and cut, the placenta and umbilical cord are cleaned. The cord blood is put into a sterile container, mixed with a preservative, and frozen until needed.

Some parents choose to donate their infants cord blood to a public blood bank, so that it may be used by anyone who needs it. Many hospitals collect cord blood for donation, which makes it easier for parents to donate. Parents can donate their newborns cord blood to volunteer or public cord blood banks at no cost. For more about donating your newborns cord blood, call 1-800-MARROW2 (1-800-627-7692) or visit Be the Match.

Other parents store their newborns cord blood in private cord blood banks just in case the child or a close relative needs it someday. If you want to donate or bank (save) your childs cord blood, youll need to arrange it before the baby is born. Some banks require you to set it up before the 28th week of pregnancy, although others accept later setups. Among other things, youll be asked to answer health questions and sign a consent form.

Parents may want to bank their childs cord blood if the family has a history of diseases that may benefit from stem cell transplant. There are several private companies offer this service. But here are some things to think about:

More information on private family cord blood banking can be found at the Parents Guide to Cord Blood Foundation. You can visit their website at http://www.parentsguidecordblood.org.

Read the rest here:
Donating Stem Cells and Bone Marrow

To Read More: Donating Stem Cells and Bone Marrow
categoriaBone Marrow Stem Cells commentoComments Off on Donating Stem Cells and Bone Marrow | dataJune 3rd, 2020
Read All

Mesenchymal Stem Cells Market trends by manufacturers, states, type and application, forecast to 2019 2027 – WhaTech Technology and Markets News

By daniellenierenberg

Mesenchymal Stem Cells Market Trends by Manufacturers, States, Type and Application, Forecast to 2019 2027

Global Mesenchymal Stem Cells Market: Snapshot

The increasing use of mesenchymal stem cells (MSCs) for the treatment of diseases and disabilities of the growing aging population is having a positive influence on the global mesenchymal stem cells market. Mesenchymal stem cells are adult stem cells that are of various types such as adipocytes, osteocytes, monocytes, and chondrocytes.

The main function of mesenchymal stem cells is to replace or repair damaged tissue.

Report Overview @www.transparencymarketresearch.com/mesencharket.html

Mesenchymal stem cells are multipotent, i.e. they can produce more than one type of specialized cells.

These specialized cells have their own distinguishing shapes, structures, and functions, with each of them belonging to a particular tissue.

Mesenchymal stem cells are traditionally found in the bone marrow. However, these cells can also be separated from other tissues such as cord blood, fallopian tube, peripheral blood, and fetal liver and lung.

Mesenchymal stem cells have long thin cell bodies containing a large nucleus. MSCs have enormous capacity for renewal keeping multipotency.

Due to these virtues, mesenchymal stem cells have huge therapeutic capacity for tissue repair.

Get Brochure of the Report @www.transparencymarketresearch.com/sample/p_id=26735

Mesenchymal stem cells can differentiate into a number of cell types that belong to our skeletal tissues that include cartilage, bone, and fat. Research is underway to discover if mesenchymal stem cells can be used to treat bone and cartilage diseases.

Scientists are also exploring the possibility if mesenchymal stem cells differentiate into other type of cells apart from skeletal tissues. This includes nerve cells, liver cells, heart muscle cells, and endothelial cells.

This will lead to mesenchymal stem cells to be used to treat other diseases.

Stem cells are specialized cells which have the capability of renewing themselves through cell division and differentiate into multi-lineage cells. Mesenchymal stem cells (MSCs) are non- hematopoietic, multipotent adult stem cells which can be isolated from bone marrow, cord blood, fat tissue, peripheral blood, fallopian tube, and fetal liver and lung tissue.

Request For Covid19 Impact Analysis http://www.transparencymarketresearch.com/sample/p_id=26735

Mesenchymal stem cells have the capacity to differentiate into mesodermal lineages, such as chondrocytes, adipocytes, and osteocytes, and non-mesodermal lineages such as ectodermal (neurocytes) and endodermal lineages (hepatocytes). These stem cells have specific features such as multilineage potential, secretion of anti-inflammatory molecules, and immunomodulation.

These cells have emerged as promising therapeutic agents for regenerating skeletal tissues such as damaged bone and cartilage tissues and treatment of chronic diseases owing to their specific features.

The global mesenchymal stem cells market is expected to be driven by the increasing clinical application of mesenchymal stem cells for the treatment of chronic diseases, bone and cartilage diseases, and autoimmune diseases. Studies have shown that these stem cells enhance the angiogenesis in myocardium and allow the reduction of myocardial fibrotic area.

The pre-clinical studies for using mesenchymal stem cells in treatment of cardiovascular diseases, liver diseases, and cancer are projected to create new market opportunities for mesenchymal stem cells. Mesenchymal stem cells also produce anti-inflammatory molecules which modulate humoral and cellular immune responses.

Features of these stem cells such as ease of isolation, regenerative potential, and immunoregulatory, the mesenchymal stem cell therapy has emerged as a promising tool for the treatment of chronic diseases, degenerative, inflammatory, and autoimmune diseases.

Pre Book Now @www.transparencymarketresearch.com/checkoump;ltype=S

Clinical studies are exploring MSCs for various conditions such as orthopedic injuries, graft versus host disease following bone marrow transplantation, and genetic modification of MSCs to overexpress antitumor genes for use as anticancer therapy, which are exhibiting new opportunities in therapeutic area. However, the mesenchymal stem cell research studies are tedious, lengthy, and complex.

In some cases, due to some adverse effects transplanted mesenchymal stem cells rapidly removed from the body which limits use of stem cells in therapeutic treatments. The conflicting results and regulatory compliances for approvals may also hamper the growth of this market.

The global mesenchymal stem cells market is segmented on the basis of source of isolation, end-user, and region. Stem cells are isolated from the bone marrow, peripheral blood, lung tissue, umbilical cord blood, amniotic fluids, adipose tissues, and synovial tissues.

Traditionally the MSCs were isolated from bone marrow aspiration which is associated with risk of infection and painful for the patient. The MSCs from adipose tissues are usually isolated from the biological material generated during liposuction, lipectomy procedures by using collagenase enzymatic digestion followed by centrifugation and washing.

In terms of end-user, the market is segmented into clinical research organizations, biotechnological companies, medical research institutes, and hospitals.

Read our Case study at :www.transparencymarketresearch.com/casestug-start-up

Geographically, the global mesenchymal stent cells market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market and is projected to continue its dominance in terms of market share during the forecast period owing to high R&D expenditure, availability of advanced research facilities and skilled professionals, and government initiatives.

Europe is the second largest market after North America. The Asia Pacific market is projected to expand at a high CAGR during the forecast period due to increased R&D budgets in Japan, China, and India.

Key global players operating in the mesenchymal stem cells market include R&D Systems, Inc., Cell Applications, Inc., Axol Bioscience Ltd., Cyagen Biosciences Inc., Cytori Therapeutics Inc., Stemcelltechnologies Inc., BrainStorm Cell Therapeutics, Stemedica Cell Technologies, Inc., and Celprogen, Inc.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Read this article:
Mesenchymal Stem Cells Market trends by manufacturers, states, type and application, forecast to 2019 2027 - WhaTech Technology and Markets News

To Read More: Mesenchymal Stem Cells Market trends by manufacturers, states, type and application, forecast to 2019 2027 – WhaTech Technology and Markets News
categoriaBone Marrow Stem Cells commentoComments Off on Mesenchymal Stem Cells Market trends by manufacturers, states, type and application, forecast to 2019 2027 – WhaTech Technology and Markets News | dataJune 3rd, 2020
Read All

Myelofibrosis Treatment Market to Create Lucrative Opportunities for Existing Companies as Well as New Players – Cole of Duty

By daniellenierenberg

Myelofibrosis or osteomyelofibrosis is a myeloproliferative disorder which is characterized by proliferation of abnormal clone of hematopoietic stem cells. Myelofibrosis is a rare type of chronic leukemia which affects the blood forming function of the bone marrow tissue. National Institute of Health (NIH) has listed it as a rare disease as the prevalence of myelofibrosis in UK is as low as 0.5 cases per 100,000 population. The cause of myelofibrosis is the genetic mutation in bone marrow stem cells. The disorder is found to occur mainly in the people of age 50 or more and shows no symptoms at an early stage. The common symptoms associated with myelofibrosis include weakness, fatigue, anemia, splenomegaly (spleen enlargement) and gout. However, the disease progresses very slowly and 10% of the patients eventually develop acute myeloid leukemia. Treatment options for myelofibrosis are mainly to prevent the complications associated with low blood count and splenomegaly.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/11341

The global market for myelofibrosis treatment is expected to grow moderately due to low incidence of a disease. However, increasing incidence of genetic disorders, lifestyle up-gradation and rise in smoking population are the factors which can boost the growth of global myelofibrosis treatment market. The high cost of therapy will the growth of global myelofibrosis treatment market.

The global market for myelofibrosis treatment is segmented on basis of treatment type, end user and geography:

As myelofibrosis is considered as non-curable disease treatment options mainly depend on visible symptoms of a disease. Primary stages of the myelofibrosis are treated with supportive therapies such as chemotherapy and radiation therapy. However, there are serious unmet needs in myelofibrosis treatment market due to lack of disease modifying agents. Approval of JAK1/JAK2 inhibitor Ruxolitinib in 2011 is considered as a breakthrough in myelofibrosis treatment. Stem cell transplantation for the treatment of myelofibrosis also holds tremendous potential for market growth but high cost of therapy is foreseen to limits the growth of the segment.

On the basis of treatment type, the global myelofibrosis treatment market has been segmented into blood transfusion, chemotherapy, androgen therapy and stem cell or bone marrow transplantation. Chemotherapy segment is expected to contribute major share due to easy availability of chemotherapeutic agents. Ruxolitinib is the only chemotherapeutic agent approved by the USFDA specifically for the treatment of myelofibrosis, which will drive the global myelofibrosis treatment market over the forecast period.

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/11341

Geographically, global myelofibrosis treatment market is segmented into five regions viz. North America, Latin America, Europe, Asia Pacific and Middle East & Africa. Northe America is anticipated to lead the global myelofibrosis treatment market due to comparatively high prevalence of the disease in the region.

Some of the key market players in the global myelofibrosis treatment market are Incyte Corporation, Novartis AG, Celgene Corporation, Mylan Pharmaceuticals Ulc., Bristol-Myers Squibb Company, Eli Lilly and Company, Taro Pharmaceuticals Inc., AllCells LLC, Lonza Group Ltd., ATCC Inc. and others.

Here is the original post:
Myelofibrosis Treatment Market to Create Lucrative Opportunities for Existing Companies as Well as New Players - Cole of Duty

To Read More: Myelofibrosis Treatment Market to Create Lucrative Opportunities for Existing Companies as Well as New Players – Cole of Duty
categoriaBone Marrow Stem Cells commentoComments Off on Myelofibrosis Treatment Market to Create Lucrative Opportunities for Existing Companies as Well as New Players – Cole of Duty | dataJune 3rd, 2020
Read All

Human Mesenchymal Stem Cells (hMSC) Market investigated in the latest research – WhaTech Technology and Markets News

By daniellenierenberg

Human Mesenchymal Stem Cells (hMSC) Market Sales 2020-2026

Worldwide Human Mesenchymal Stem Cells (hMSC) Market Report 2020-2026 is a systematic and insightful compilation of valuable evaluations of Human Mesenchymal Stem Cells (hMSC) market and relevant aspects. The report offers an in depth exploration of the market and its scope, trends, structure, production, profitability and maturity.

The precise evaluation of market size, share, revenue, sales volume, demand, and rate of growth involved within the report drive investors, industry experts, researchers, also as novice and well-established market players to grasp the general Human Mesenchymal Stem Cells (hMSC) market structure.

Report: calibreresearch.com/report/est-sample The Human Mesenchymal Stem Cells (hMSC) market report also delivers an in-depth analysis of the emerging industry trends along side the restraints, key players, and opportunities within the Human Mesenchymal Stem Cells (hMSC) market to supply worthwhile insights also as a gift scenario for generating right decision.

Moreover, the new report on the Human Mesenchymal Stem Cells (hMSC) industry covers the prominent vendors within the universal market alongside SWOT analysis, fiscal overview and major developments. The world Human Mesenchymal Stem Cells (hMSC) Market report is considered as a detailed investigation of the respective market that will provide key solutions for establishment of profit-driven business strategies.

It is helpful for offering details about futuristic Human Mesenchymal Stem Cells (hMSC) industry trends and in-depth assessment of the international industry. It permits you to determine remarkable challenges and risk factors alongside major opportunities available in the world Human Mesenchymal Stem Cells (hMSC) market.

This report also exhibits the whole historical and current status of the Human Mesenchymal Stem Cells (hMSC) Market worldly. Apart from this, the report on the Human Mesenchymal Stem Cells (hMSC) industry also represents the graphical representation of the upcoming Human Mesenchymal Stem Cells (hMSC) Market infrastructure and the Compound Annual Growth Rate (CAGR) in detail.

Report: calibreresearch.com/report/for-buying

The report on the Human Mesenchymal Stem Cells (hMSC) market is an exclusive and deep study which delivers a comprehensive overview of the industry contains the recent trends and future proportions of the Human Mesenchymal Stem Cells (hMSC) market in terms of product and services. Meanwhile, this report offers a professional research study on the Human Mesenchymal Stem Cells (hMSC) market so as to guage the remarkable vendors by calibrating all the relevant products or services to know the positioning of the key players within the Human Mesenchymal Stem Cells (hMSC) market worldly.

Leading companies reviewed in the Human Mesenchymal Stem Cells (hMSC) report are: PromoCell ThermoFisher KURABO Lifeline Cell Technology Merck The Human Mesenchymal Stem Cells (hMSC) Market report is segmented into following categories: The product segment of the report offers product market information such as demand, supply and market value of the product. The application of product in terms of USD value is represented in numerical and graphical format for all the major regional markets.

The Human Mesenchymal Stem Cells (hMSC) market report is segmented into Type by following categories; Umbilical Cord Matrix hMSC Bone Marrow hMSC Adipose Tissue hMSC Other The Human Mesenchymal Stem Cells (hMSC) market report is segmented into Application by following categories; Medical Application Research Other Applications

Report: calibreresearch.com/report/est-sample

The world Human Mesenchymal Stem Cells (hMSC) marketing research report offers an in depth summary of the foremost desirable factors and informative details about the universal industry. Moreover, the study provides an in-depth summary and forecast of the worldwide Human Mesenchymal Stem Cells (hMSC) market on the idea of several segments.

This report also delivers Human Mesenchymal Stem Cells (hMSC) market size and predicted estimations from the year 2020 to 2026 concerning various topological regions including Europe, North America, the center East and Africa, and South America. The research study on the Human Mesenchymal Stem Cells (hMSC) Market is a valuable source of guidance for world customers as it will rapidly fulfil their requirement and speed up their business growth.

It is an advantageous document for both existing industries manufactures including end-user industries, experts, managers, stakeholders and new entrants. We have designed this world Human Mesenchymal Stem Cells (hMSC) Market report in a deeply understandable format so that anyone can grasp each and every aspect related to the respective industry.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Originally posted here:
Human Mesenchymal Stem Cells (hMSC) Market investigated in the latest research - WhaTech Technology and Markets News

To Read More: Human Mesenchymal Stem Cells (hMSC) Market investigated in the latest research – WhaTech Technology and Markets News
categoriaBone Marrow Stem Cells commentoComments Off on Human Mesenchymal Stem Cells (hMSC) Market investigated in the latest research – WhaTech Technology and Markets News | dataJune 3rd, 2020
Read All

DKMS-BMST Foundation India completes one year of operation in India – Express Healthcare

By daniellenierenberg

Celebrates milestone with registration of over 42,000 potential life savers in same time period in country

This World Blood Cancer Day, DKMS-BMST celebrates a milestone of registering over 42,000 potential lifesavers in a time period of one year in India. This group comprises of individuals who range from 18-50 years of age and have pledged to donate their blood stem cells to a blood cancer patient in need.

Focussed on helping patients with blood cancer and other blood disorders, DKMS-BMST has been able to save28unique lives in this period of one year including children diagnosed with blood cancer and other blood disorders like thalassemia.

Patients affected by blood cancer or thalassemia need a blood stem cell donation. Worldwide, only 30 per cent of them can find a match within their families and hence there is a dire need to find an unrelated donor. We started our operations in India last year with an intent to add potential blood stem cell donors of Indian ethnicity to the global database, so that patients (especially from this unique ethnicity) living in different parts of the world have a fair chance of finding a match and probably gain a second chance at life. We cannot thank enough, the people who are on-board and are helping us spread the word to add more and more people to this database,said Paul Patrick, CEO, DKMS BMST Foundation India.

Sharing his experience Mohd Saifulla, father to a 4-year-old thalassemia survivor said We went to multiple doctors trying to assess the problem our child had and thereafter to find a matching donor who could save her life. Receiving this transplant was the only chance of life for my daughter and we can never thank Debojyoti, a 28 year old software professional, enough, who donated his blood stem cells that matched our daughter. It is only because of organisations such as DKMS-BMST that people are coming forward to donate blood stem cells and save a life. My entire family is indebted to them for lifetime. Today my daughter is living a happy and healthy life and we are preparing to celebrate her fifth birthday this year that seemed like a dream to us up till a few years back.

Last year on World Blood Cancer Day, DKMS, one of the largest international blood stem cell donor centres in the world dedicated to the fight against blood cancer and blood disorders joined forces with Bangalore Medical Service Trust (BMST), a centre of excellence in blood banking, transfusion and immunohaematology adding India to the largest global repository of potential blood stem cell donors in the world. Every year, over 100,000 people in India are diagnosed with blood cancer or a blood disorder such asthalassemia or aplastic anaemia. Such life-threatening conditions can be managed by infusing a set of healthy blood stem cells from a suitable match. Since,ethnicity plays a crucial role in finding a matching donor, the ratio of potential blood stem cell donors from India needs to rise significantly, said Dr Latha Jagannathan, Director, DKMS BMST Foundation India.

Harsh, a blood stem cell donor registered with the foundation said,With very limited knowledge about blood stem cells I believed they were present only in the bone marrow and extracting them was a complex process. But to my surprise, the process is very similar to blood platelet donation. I strongly feel that anyone who is made aware that a simple process with zero complications can give you a chance to save a life will not hesitate from committing themselves towards the cause.

Capturing the challenges, the NGO faced in the country,Patrick said,We realised very early in India that a decision of this nature is not alone of the donor, but also involves his / her family. Hence, explaining the process, inculcating right awareness to break myths, updating people on the technological advances of blood stem cell donation and counselling them with medical experts has been our modus operandi in the country. Thus far, we have been able to conduct many physical drives to reach out to people urging them to register as potential donors. We plan to expand our reach to many more regions this year so that we are able to add potential donors from varied population groups in the country.

DKMS-BMST has organised over 1000donor registration drives in one year across various organisations such as corporates, educational institutes, hospitals and defence forces to spread awareness about blood stem cell donation and enroll more potential donors. Few names where physical drives have been conducted includes Mindtree, HSBC, HP enterprises, Christ University, RV College of Engineering, apart from public drives at Orion Mall Bengaluru, Lalbagh Botanical Garden etc.

In the current lockdown situation, the team is working tirelessly to ensure that patients whose donations were scheduled do not face any challenges and are organising awareness sessions through webinars and calling for registrations through the online portal:www.dkms-bmst.org/register.

See more here:
DKMS-BMST Foundation India completes one year of operation in India - Express Healthcare

To Read More: DKMS-BMST Foundation India completes one year of operation in India – Express Healthcare
categoriaBone Marrow Stem Cells commentoComments Off on DKMS-BMST Foundation India completes one year of operation in India – Express Healthcare | dataJune 3rd, 2020
Read All

Alternative and Complementary Treatments for Cancer – HealthCentral.com

By daniellenierenberg

On this page:BasicsComplementary TreatmentAlternative Treatment EffectivenessSide EffectsCancer Cure ScansDiet and Exercise

Youve seen the headlines about natural medicine trends, from yoga to supplements to diet and exercise fads. When it comes to cancer, you want to know what will help you safely regain your health during treatment and after. But there are loads of competing, sometimes-confusing info to sift through. What can you trust? Well, you can start with us here at HealthCentral: We went to the experts to learn all the science-based truth on complementary care for cancer.

First, lets clarify how cancer comes to be: Cancer occurs when abnormal cells anywhere in your body grow out of control, due to mutations in their DNA. Normal cells divide, age and die predictably, copying DNA as they go. Cancer cells, however, dont follow those rules. Rather than die off, they mutate, replicate, and form tumors.

Whats known as the primary site of your cancer is the spot where these cells start growing, and that organ or area determines the type of cancer you have. When cancerous cells journey through your blood or lymphatic system (the network of tissues and organs that flush out toxins, waste, and other undesirables), the areas they invade are metastatic sites.

Note that a cell can be abnormal without being cancerous (also known as malignant). It could be benign (not cancer), or precancerous or premalignant (likely to become cancer). Through screening and testing, docs can determine exactly what youre dealing with.

That depends on what kind of cancer you have, what stage its in, and other factors. Treatment can include:

Doctors often try more than one treatment, spaced out over weeks and months, as they gauge how your body responds. Your doc might even start you on multiple treatments at the same time.

Youve probably heard of complementary care. Or maybe you know it as alternative care. You know a bit of what these treatments might include (youre thinking meditation, herbs, and maybe yoga?). But did you know that while complementary and alternative care are often lumped together (as CAM, Complementary and Alternative Medicine), theyre not the same?

Complementary medicine is used in addition to conventional cancer care. It can include products, practices, and healthcare systems outside of mainstream medicine. These methods dont cure cancer, but work in conjunction with conventional cancer treatments to help in a variety of ways, including pain management and emotional support. Many complementary medicine practices can be considered evidence-based medicine (scientifically studied in randomized controlled trials, the highest level of evidence that guides cancer care).

When complementary medicine works harmoniously with conventional medicine, its an approach known as integrative medicine, or integrated care, where physicians treat you holisticallymeaning caring for you as a whole patient, taking into account all facets of your cancer experience. These can include:

When integrative medicine is administered to treat cancer, its known as integrative oncology, a patient-centered, evidence-informed field of cancer care. It may include:

Alternative medicine, in contrast, is used in place of conventional medicine. Rather than going hand-in-hand with, say surgery and chemo, alternative medicine is done instead of those evidence-based cancer treatments.

A quick note: before you try any new approach during (and after) your cancer treatment journey, make sure to discuss it with your doctor.

If youve used or are considering using complementary medicine as a cancer patient, youre not alonea national survey found that 65% of respondents whod been diagnosed with cancer had used some form of it.

Theres good reason to explore complementary care if you have cancer. It can be part of your supportive carehelping where you need it, like soothing and calming your mind and body as you go through this challenging time. Indeed, research suggests that complementary medicine can assist by:

There are easily hundreds of complementary treatments for cancer, so weve selected a small sample to discuss here. Possibilities include:

Acupuncture: Theres substantial evidence that this ancient Chinese practice of using sterile needles to stimulate different areas of the body can help manage cancer treatment-related nausea and vomiting. It may also help relieve cancer pain and other symptoms, but theres not enough evidence yet to support that.

Herbs: Ginger, for instance, has been shown to help control nausea from chemotherapy when used with conventional anti-nausea medications. Just keep in mind that any supplements you consume can change your body physiologicallynothing you ingest is without the potential for adverse effects. For instance, herbs can impact blood sugar levels and the bloods ability to clot.

Massage therapy: Sure, it feels sublime, and it turns out to have additional benefits too: research suggests that massage therapy can help relieve some cancer symptoms including:

Just be careful not to have deep tissue massage near surgery sites, tumors, or any medical devices. And always tell your therapist about your cancer diagnosis.

Meditation: Mindfulness-based meditation has been shown to improve quality of life during treatment. How? Studies of cancer patients have revealed the following happiness-boosting benefits:

Supplements: Herbal supplements for cancer could potentially help manage side effects like nausea and vomiting, pain, and fatigue, but more scientific evidence is required to make safe decisions about the use of these supplements.

Yoga: Preliminary data of this ancient mind/body practice from India suggests that those who do yoga could see improvements in these areas:

Another benefit: It might help lessen fatigue in breast cancer patients and survivors. More study into the myriad benefits of yoga is needed.

Other approaches: These include hypnosis, relaxation therapy, and biofeedback, all of which might help manage cancer symptoms and treatment side effects, based on study results.

One thing to note about all of these approaches: they might not be covered by your health insurance. According to the American Cancer Society, major insurers, including Blue Cross and Medicare, are starting to cover some complementary treatments. On the list above, acupuncture is most commonly covered. Contact your insurer to see what complementary treatments, if any, are paid for. They might be able to direct you to local providers who are covered under your plan.

When the treatments we discussed earlier (and the hundreds of others that are offered) are used in place of conventional medicine, its known as an alternative treatment. Nearly 40%, or 4 out of 10 Americans, believes that cancer can be cured by alternative treatments, a 2018 survey of cancer patients and people without cancer, found. However, while research shows that complementary medicine can play an important role in conventional cancer medicine, the same hasnt been readily found for alternative treatment.

Case in point: in 2009, the Society for Integrative Oncology (the leading international organization for healthcare professionals and researchers working in the field of complementary therapies in cancer care) published guidelines for healthcare professionals when using complementary medicine.

The org reminded healthcare professionals and patients that unproven cancer treatment methods shouldnt be used in place of conventional options because delaying cancer treatment thats evidence-based and shown to work reduces the chance of remission/cure for cancer patients.

Its important to talk with your healthcare professionals about the risks of using alternative therapies so you can make an informed decision about whats best for your health.

There are definite side effects with CAM. You might think that because something is natural, its safe. But this isnt always the case. Arsenic is natural, for instance, but you wouldnt want to start taking it in large doses.

Another example: Chemotherapy has a multitude of side effects because it destroys both cancerous cells and healthy cells. Its been cited by many as harmful because its made from chemicals. But did you know, some forms of chemo come from nature? Three drugs (Vincristine, Vinblastine, and Vinorelbine) are derived from plant alkaloids and are made from the periwinkle plant (Catharanthus Rosea). Chemo drugs called taxanes (Paclitaxel and Docetaxel) come from the bark of the Pacific Yew tree (Taxus).

Know too that just because something is sold, doesnt mean its been vetted or approved for usefor safety or qualityby the U.S. Food and Drug Administration (FDA). The FDA doesnt regulate vitamins and supplements, so the onus is on us to do our best to source safe, trustworthy products.

Its vital to tell your cancer healthcare team about every treatment and therapy youre using for your cancer, whether its receiving acupuncture for nausea, going to the chiropractor for pain, adding St. Johns Wort to your supplement regime to help manage depression, or getting a massage to feel better.

If youre reluctant to be open with your doc, youre not alone: 29% of cancer patients did not disclose their CAM practices to their providers, according to one study. Secret-keeping could be downright dangerous. Lets use these four seemingly innocuous examples to illustrate why:

Being open with your doc--both before you start a complementary treatment and while youre on it--is key to helping it complement, rather than detract, from the conventional care youre receiving.

When you have cancer, you of course want a cure (as quickly and painlessly as possible, please). But that desire can leave you vulnerable to fake claims, especially in the alternative medicine space. Both the FDA and the Federal Trade Commission (FTC) regularly warn the public about fraudulent cancer treatments.

It can be hard to spot the signs of snake oil. Without a medical degree, how can you be wise to empty promises? Youll often see the same language used in cancer CAM scams, according to the FDA. These phrases should raise a red flag that a treatment is just too good to be true:

Heres how you can protect yourself while receiving evidence-based integrated care:

You might be wondering now: with all this talk of complementary and alternative medicine, what about food? And diet? And exercise? What role does it play in all this? Is there a cancer diet that could be a complementary treatment?

Turns out, theres a strong body of evidence that a healthy diet and regular physical activity are associated with a reduced risk of cancer. The scientific literature links nutrition to cancer prevention based on specific physiologic pathways, including reducing inflammation, regulating hormones, and preventing oxidative stress. Even after a cancer diagnosis, by making smart choices about what they put on their plate, patients can:

Food has power. To wield it, the American Institute for Cancer Research and American Cancer Society recommends you:

As for physical activity? While you should talk to your healthcare team about what kind and amount of exercise is safe during treatment, The American College of Sports Medicine (ACSM) has issued guidelines for physical activity for cancer survivors, suggesting 150-300 minutes per week of moderate to vigorous physical activity. Exercise is a real magic pill, helping to:

As you can imagine, all of these benefits that come along with being active are particularly important when youre trying to put cancer behind you. Resistance training, in particular, has been proven to improve:

Exercise, like so many CAM options, can help you both feel stronger and respond to treatment better. Just as with other types of complementary treatments, youll want to talk to your doc about how to integrate it, so you can reap the maximum benefits both from your lifestyle changes and your conventional cancer treatment.

Researchers have found that a healthy diet is associated with a reduced risk of cancer. Even if you have cancer, it can help lessen the impact of side effects and improve your quality of life. Studies link nutrition to cancer prevention based on specific physiologic pathways, including reducing inflammation, regulating hormones, and preventing oxidative stress. All to say that food matters.

Heres the thing: there are therapies that can help you go into remission (the period when your signs and symptoms of cancer are reduced). And some healthcare professionals consider cancer cured if it hasnt returned after five years (also called complete remission). Treatments that achieve a complete remission/cure can include therapies that come from a natural source, like some forms of chemo, which are derived from plant alkaloids. But anyone promising a natural cure for cancer that doesnt have evidence to back up that claim is likely pedaling bunk.

As weve discussed, herbs can be excellent complementary treatment in oncology for things like nausea, but any claim of curing cancer should be tempered by evidence-based medicine results (meaning, proof to back up those claims).

The American Academy of Dermatology warns that black salve isnt as safe as you might think, stating that it has never been proven to work. An article on the AADs website cites reports of bad outcomes for people who tried to treat their cancer (including melanoma) using black salve. The U.S. Food and Drug Administration (FDA) warns against products that are touted as cures for cancer without evidence: The FDA urges consumers to steer clear of these potentially unsafe and unproven products and to always discuss cancer treatment options with their licensed health care provider.

Read the original here:
Alternative and Complementary Treatments for Cancer - HealthCentral.com

To Read More: Alternative and Complementary Treatments for Cancer – HealthCentral.com
categoriaBone Marrow Stem Cells commentoComments Off on Alternative and Complementary Treatments for Cancer – HealthCentral.com | dataJune 3rd, 2020
Read All

Covid 19 Outbreak Cell Harvesting System Market 2020 Product Type, Applications/end user, Key Players and Geographical Regions 2026 – Jewish Life…

By daniellenierenberg

COVID-19 impact will also be included and considered for forecast.

Global Cell Harvesting System Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.

Cell Harvesting System Market Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast And Business Opportunity.

>>Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=153&RequestType=Sample

Cell Harvesting System Market: Increase in healthcare facilities and increase in bone marrow transplantation are key drivers for the Global Cell Harvesting System Market.

The global cell harvesting systems market size was valued USD 3533.27 Million in 2017 and is expected to grow at a CAGR of 14.01% over the forecast period.

Cell harvesting is a system which is used to cultivate, regenerate, transplant and repair the damages organs with the healthy one. Cell harvesting is one of the important parts of biopharmaceutical industry which directly relates with the quality of product. Stem cell harvesting also helps in the treatment of various diseases such as cancer, autoimmune disease, anemia and others. So, during the study of Global Cell Harvesting System market, we have considered Cell Harvesting System to analyze the market.

Global Cell Harvesting System Market report is segmented on the technique type, application type, end user type and by regional & country level. Based upon technique type, global Cell Harvesting System Market is classified as Altered Nuclear Transfer and Blastomere Extraction. Based upon Application type, global Cell Harvesting System Market is classified as Bone Marrow, Peripheral Blood, Umbilical Cord Blood, and Adipose Tissue. Based upon end users, global Cell Harvesting System Market is classified as Research Centers, Academics Institutes, Diagnostic Labs, and Hospitals.

The regions covered in this Cell Harvesting System Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Cell Harvesting System is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Cell Harvesting System Market Reports

Global Cell Harvesting System market report covers prominent players like Tomtec, Bertin Technologies, PerkinElmer Inc., TERUMO BCT, INC., SP Scienceware, hynoDent AG, Avita Medical, BRAND GMBH Teleflex Incorporated., Argos Technologies, Inc., Thomas Scientific, Arthrex, Inc. and others.

Global Cell Harvesting System Market Dynamics

The commercialization and growth of global Cell Harvesting System market over the past 25 years has been highly impactful. Bone marrow transplantation is one of the major factors driving the growth of cell harvesting system over the forecast period. Due to the increase in blood cancer it has raised the demand for bone marrow transplantation which in turn increased the demand for cell harvesting system. As per The Leukemia & Lymphoma Society report 2018, an estimated combined total of 174,250 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2018. There is also an increase in awareness about stem cells and its advantages which are helpful in the treatment of various disorders. Furthermore, various technological advancement have also increase the new and better technologies with better results are expected to promote the growth of cell harvesting system market over the forecast period. However, High cost, lack of reimbursement policies, immune rejection and others are the various factors which are expected to hamper the growth of cell harvesting system market over the forecast period.

Global Cell Harvesting System Market Regional Analysis

North America dominates the market with highest market share which is closely followed by the Europe over the forecast period. Due to the increased prevalence of leukemia, lymphoma and others coupled with increased healthcare facilities. As per The Leukemia & Lymphoma Society 2018 report, new cases of leukemia, lymphoma and myeloma are expected to account for 10 percent of the estimated 1,735,350 new cancer cases diagnosed in the US in 2018. Asia Pacific is expected to be the third largest and fastest growing region over the forecast period. Due to various technological advancements, increase in awareness among people and others are expected to support the growth of cell harvesting system market over the forecast period. Furthermore, Increase in healthcare facilities in the developing economies such as India, China and others are expected to fuel the growth of cell harvesting system market. Latin America, Middle East and Africa and expected to develop at a considerable rate over the forecast period.

Key Benefits for Global Cell Harvesting System Market Reports

Global Cell Harvesting System market report covers in depth historical and forecast analysis.Global Cell Harvesting System Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.Global Cell Harvesting System Market report helps to identify opportunities in market place.Global Cell Harvesting System Market report covers extensive analysis of emerging trends and competitive landscape.

By Techniques Type:

Altered Nuclear TransferBlastomere Extraction

By Application:

Bone MarrowPeripheral BloodUmbilical Cord BloodAdipose Tissue

By End User:

Research CentersAcademics InstitutesDiagnostic LabsHospitals

By Region

North AmericaU.S.CanadaEuropeUKFranceGermanyItalyAsia PacificChinaJapanIndiaSoutheast AsiaLatin AmericaBrazilMexicoThe Middle East and AfricaGCCAfricaRest of Middle East and Africa

Cell Harvesting System Market Key PlayersTomtecBertin TechnologiesPerkinElmer Inc.TERUMO BCT, INC.SP SciencewarehynoDent AGAvita MedicalBRAND GMBHTeleflex Incorporated.Argos Technologies, Inc.Thomas ScientificArthrex, Inc.

Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=153&RequestType=Methodology

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Cell Harvesting System Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Global Cell Harvesting System Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Cell Harvesting System Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Cell Harvesting System Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Cell Harvesting System Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Cell Harvesting System Market.

Market Forecast: Here, the report offers a complete forecast of the Global Cell Harvesting System Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

Top Trending Reports:

Continue reading here:
Covid 19 Outbreak Cell Harvesting System Market 2020 Product Type, Applications/end user, Key Players and Geographical Regions 2026 - Jewish Life...

To Read More: Covid 19 Outbreak Cell Harvesting System Market 2020 Product Type, Applications/end user, Key Players and Geographical Regions 2026 – Jewish Life…
categoriaBone Marrow Stem Cells commentoComments Off on Covid 19 Outbreak Cell Harvesting System Market 2020 Product Type, Applications/end user, Key Players and Geographical Regions 2026 – Jewish Life… | dataJune 3rd, 2020
Read All

Hesperos demonstrates innovative Human-on-a-Chip approach to modeling innate immune system response following tissue damage and acute inflammation -…

By daniellenierenberg

ORLANDO, Fla.--(BUSINESS WIRE)--Hesperos Inc., pioneers of the Human-on-a-Chip in vitro system, today announced the publication of a new peer-reviewed publication that describes how the companys technology can be used to investigate immune responses following treatment with biological therapeutics for multi-organ systemic diseases, including cancer, infectious diseases and inflammatory disorders. The study was part of a collaboration between Hesperos, Hoffman-La Roche Pharmaceuticals and the University of Central Florida. The manuscript, titled Differential Monocyte Actuation in a Three-Organ Functional Innate Immune System-on-a-Chip, was published today in the prestigious journal Advanced Science. Click here to view a multimedia version of the press release, including media-ready images, downloadable resources, and more.

The immune system plays an important role in coordinating with other organ systems to combat infection, eliminate damaged cells and repair tissue. However, modeling immune response following drug treatment in preclinical studies is challenging due to poor predictability, especially for the innate portion of the system. As the scientific community begins to turn more towards using multi-organ, human-on-a-chip systems as a cost-effective way to increase efficiency and lower toxicity, many of these models lack a systemic immune component.

Hesperos, in collaboration with Hoffmann-La Roche Pharmaceuticals, describe an in vitro, pumpless, three-organ system containing functional human cardiomyocytes, skeletal muscle and hepatocytes in a serum-free medium, along with recirculating human monocyte THP-1 immune cells. Monocytes are a vital immune system cells involved in wound healing, pathogen clearance and activation of the innate immune response, but are also responsible for the cytokine storm found in conditions such as sepsis.

One application where the immune-system-on-a-chip can be immediately useful is for uncovering how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly affects multi-organ systems by activating the cytokine storm from inflammatory macrophages and to support the rapid development of therapeutics. As the global pandemic of COVID-19 continues to grow, this system has the potential to quickly evaluate antiviral and repurposed drugs to help combat this devastating disease, said Michael L. Shuler, Ph.D., Chief Executive Officer of Hesperos.

In the study, the researchers evaluated two different innate immune responses: 1) targeted immune response following tissue-specific damage, which simulates indirect activation of THP-1 cells and, 2) pro-inflammatory immune response following direct activation of immune cells, mimicking acute inflammation and the cytokine storm. Though not reported in this study, Hesperos has also shown that peripheral blood mononuclear cells (PBMCs) and T-cells are sustainable in these multi-organs systems, which would allow some aspects of adaptive immunity to also be modeled.

In the targeted immune response experiments, the cardiotoxic compound amiodarone was used to selectively damage cardiac cells to evaluate how THP-1 immune cells affect the three-organ system. The presence of both amiodarone and THP-1 immune cells led to a more pronounced reduction in cardiac force, conduction velocity and beat frequency compared to amiodarone alone. THP-1 cells were also found to infiltrate the damaged cardiomyocytes and induce significantly increased cytokine IL-6 expression, indicating an M2 macrophage phenotype. No immune-activated damage was reported in the skeletal muscle or liver cells.

The most striking features of our immune-system-on-a-chip is that it emulates different immune reactions for direct tissue-damage and acute inflammation, as well as distinguishes between M1 vs. M2 macrophage phenotypes, said James Hickman, Ph.D., Chief Scientist at Hesperos and Professor at the University of Central Florida.

The study was initially funded by Roche Pharmaceuticals and completed under an NIH grant from National Center for Advancing Translational Sciences (NCATS) Small Business Innovation Research program, which supports studies to advance tissue chip technology toward commercialization.

Tissue chips are a promising technology for accelerating the preclinical timeline and getting treatments to patients more efficiently, said Danilo A. Tagle, Ph.D., associate director for special initiatives at NCATS. Finding improved ways to study immune responses has tremendous implications for drug discovery and the development of more effective personalized medicines in diseases that affect multiple organ systems.

In the pro-inflammatory response experiments, the three-organ system was exposed to lipopolysaccharide (LPS) and interferon gamma (IFN-) to stimulate acute inflammation/cytokine storm and provoke monocyte differentiation and activation. In the absence of THP-1 immune cells, LPS/IFN- treatment had no significant effect on function of the three-organ system. However, with the addition of THP-1 immune cells, LPS/IFN- treatment caused cellular damage to all three-organ components, including THP-1 cell infiltration in liver tissue, and led to significant alterations in cardiac force and beat frequency, as well as skeletal muscle force. Additionally, there was an upregulation of pro-inflammatory cytokines, including TNF-, IL-6 and IL-10, indicating an M1 macrophage phenotype, which is analogous to the cytokine storm found during certain reactions to biologic therapeutics and emulates what occurs during sepsis.

To read the full manuscript, please visit https://doi.org/10.1002/advs.202000323.

About Hesperos

Hesperos, Inc. is a leader in efforts to characterize an individuals biology with Human-on-a-Chip microfluidic systems. Founders Michael L. Shuler and James J. Hickman have been at the forefront of every major scientific discovery in this realm, from individual organ-on-a-chip constructs to fully functional, interconnected multi-organ systems. With a mission to revolutionize toxicology testing as well as efficacy evaluation for drug discovery, the company has created pumpless platforms with serum-free cellular mediums that allow multi-organ system communication and integrated computational PKPD modeling of live physiological responses utilizing functional readouts from neurons, cardiac, muscle, barrier tissues and neuromuscular junctions as well as responses from liver, pancreas and barrier tissues. Created from human stem cells, the fully human systems are the first in vitro solutions that accurately utilize these platforms to predict in vivo functions without the use of animal models, as featured in Science. More information is available at https://hesperosinc.com

Hesperos and Human-on-a-Chip are trademarks of Hesperos Inc. All other brands may be trademarks of their respective holders.

See the rest here:
Hesperos demonstrates innovative Human-on-a-Chip approach to modeling innate immune system response following tissue damage and acute inflammation -...

To Read More: Hesperos demonstrates innovative Human-on-a-Chip approach to modeling innate immune system response following tissue damage and acute inflammation -…
categoriaCardiac Stem Cells commentoComments Off on Hesperos demonstrates innovative Human-on-a-Chip approach to modeling innate immune system response following tissue damage and acute inflammation -… | dataJune 2nd, 2020
Read All

Photoaged Skin Therapy with Adipose-Derived Stem Cells – MedicalResearch.com

By daniellenierenberg

MedicalResearch.com Interview with:

Charles-de-SM.D., Ph.D.Rio de Janeiro, Brazil

MedicalResearch.com: What is the background for this study?

Response: Our clinical trial was based on our clinical skin observations in areas submitted to a lipotransfer previously, an ordinary practice in plastic surgery. These clinical observations lead us to investigate what will be the key element played in these findings. Our scientific support investigation addressed the Dardick1and Zuk, P2 studies, that demonstrated fibroblastic-like cells in adipose tissue with regenerative ability. Our clinical trial proposal is to investigate the adipose-derived stem cell (ADSC) role in the photoaged skin. The direct endpoint of the study was to assess the histological benefits provided by the subdermal ADSC injection. Mesenchymal stem cells were obtained from lipoaspirates, expanded in vitro, and introduced into the facial skin of 20 patients submitted after three to four months to a face-lifting surgery. In the retrieved skin, immunocytochemical and ultrastructural analysis quantified elastic matrix components, cathepsin-K, metalloprotease MMP-12, and the macrophage M2 markers: CD68, CD206 and heme-oxygenase-1.An overview of the trial steps is described in the infographic.

MedicalResearch.com: What are the main findings?

Response:A full de novo formation of oxytalan and elaunin fibers was observed in the subepidermal region, with a reconstitution of the papillary structure of the dermal-epidermal junction. Elastotic deposits in the deep dermis were substituted by a normal elastin fiber network. The coordinated removal of the pathologic deposits of old elastic fibers and their substitution by the normal ones was concomitant with activation of cathepsin-K and MPP12, and with expansion of the M2 macrophage infiltration.

MedicalResearch.com: What should readers take away from your report?

Response: This study has demonstrated ADSC to remodeling the skin extra cellular matrix, mainly in the elastic system.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Response: Based on these findings, the future of thisresearch line aims to create new possibilities in regenerative cell therapy not only in skin diseases, but also in other clinical applicability in the case of organs and tissues with reduction and / or alteration in the elastic system (ex: aneurysms, cardiac valve disease and others), with a better understanding of the mechanisms involved and the control of these processes.

MedicalResearch.com: Is there anything else you would like to add? Any disclosures?

Response: It is interesting to be able, in future studies, to evaluate other mechanisms involved and the duration of effects regenerative effects on skin treated with ADSC. Another question could be considered: optimized ADSC (quantity) / area with the tissue effect found. We have not any to disclosure. This study was developed by federal university of Rio de Janeiro-Brasil and Verona University-Italy

Citation:

Charles-de-S, Luiz M.D., Ph.D.; Gontijo-de-Amorim, Natale Ferreira M.D., Ph.D.; Rigotti, Gino M.D., Ph.D.; Sbarbati, Andrea M.D., Ph.D.; Bernardi, Paolo Ph.D.; Benati, Donatella Ph.D.; Bizon Vieira Carias, Rosana Ph.D.; Maeda Takiya, Christina M.D., Ph.D.; Borojevic, Radovan Ph.D. Photoaged Skin Therapy with Adipose-Derived Stem Cells, Plastic and Reconstructive Surgery: June 2020 Volume 145 Issue 6 p 1037e-1049e doi: 10.1097/PRS.0000000000006867

References:

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

0

View post:
Photoaged Skin Therapy with Adipose-Derived Stem Cells - MedicalResearch.com

To Read More: Photoaged Skin Therapy with Adipose-Derived Stem Cells – MedicalResearch.com
categoriaCardiac Stem Cells commentoComments Off on Photoaged Skin Therapy with Adipose-Derived Stem Cells – MedicalResearch.com | dataJune 2nd, 2020
Read All

Canine Stem Cell Therapy Market Will Make a Huge Impact in Near Future – Cole of Duty

By daniellenierenberg

A synopsis of the global canine stem cell therapy market with reference to the global healthcare pharmaceutical industry

Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.

Parent Indicators Healthcare Current expenditure on health, % of gross domestic product Current expenditure on health, per capita, US$ purchasing power parities (current prices, current PPPs) Annual growth rate of current expenditure on health, per capita, in real terms Out-of-pocket expenditure, % of current expenditure on health Out-of-pocket expenditure, per capita, US$ purchasing power parity (current prices, current PPPs) Physicians, Density per 1000 population (head counts) Nurses, Density per 1000 population (head counts) Total hospital beds, per 1000 population Curative (acute) care beds, per 1000 population Medical technology, Magnetic Resonance Imaging units, total, per million population Medical technology, Computed Tomography scanners, total, per million population

Research Methodology

Get Sample Copy of this report at https://www.xploremr.com/connectus/sample/2360

XploreMR utilizes a triangulation methodology that is primarily based on experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.

Secondary research is used at the initial phase to identify the age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.

On the other hand, we also analyse various companies annual reports, investor presentations, SEC filings, 10k reports and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at Tier level based on their revenues, product portfolio and presence.

Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as per capita healthcare expenditure, disposable income, industry based demand driving factors impacting the market and its forecast trends apart from disease related factors.

Browse Full Report at https://www.xploremr.com/report/2360/canine-stem-cell-therapy-market

Standard Report Structure Executive Summary Market Definition Macro-economic analysis Parent Market Analysis Market Overview Forecast Factors Segmental Analysis and Forecast Regional Analysis Competition Analysis

Target Audience Production Companies Suppliers Channel Partners Marketing Authorities Subject Matter Experts Research Institutions Financial Institutions Market Consultants Government Authorities

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type: Allogeneic Stem Cells Autologous Stem cells

Application: Arthritis Dysplasia Tendonitis Lameness Others

End User: Veterinary Hospitals Veterinary Clinics Veterinary Research Institutes

Region: North America Latin America Europe Asia Pacific Japan Middle East & Africa

Buy Full Report at https://www.xploremr.com/cart/2360/SL

About Us

XploreMR is one of the worlds leading resellers of high-quality market research reports. We feature in-depth reports from some of the worlds most reputed market research companies and international organizations. We serve across a broad spectrum from Fortune 500 to small and medium businesses. Our clients trust us for our unwavering focus onquality and affordability. We believe high price should not be a bottleneck for organizations looking to gain access to quality information.

Contact us:XploreMR111 North Market Street, Suite 300,San Jose, CA 95113, United StatesPh.No: +16692840108

Originally posted here:
Canine Stem Cell Therapy Market Will Make a Huge Impact in Near Future - Cole of Duty

To Read More: Canine Stem Cell Therapy Market Will Make a Huge Impact in Near Future – Cole of Duty
categoriaCardiac Stem Cells commentoComments Off on Canine Stem Cell Therapy Market Will Make a Huge Impact in Near Future – Cole of Duty | dataJune 2nd, 2020
Read All

Bone Marrow Processing System Market Incisive Insights Regarding Major Regions, Key Players And Opportunities Up To 2025 – Kentucky Journal 24

By daniellenierenberg

Bone marrowaspiration and trephine biopsy are usually performed on the back of the hipbone, or posterior iliac crest. An aspirate can also be obtained from the sternum (breastbone). For the sternal aspirate, the patient lies on their back, with a pillow under the shoulder to raise the chest. A trephine biopsy should never be performed on the sternum, due to the risk of injury to blood vessels, lungs or the heart.

Get Access to sample pages @https://www.trendsmarketresearch.com/report/sample/3184

The need to selectively isolate and concentrate selective cells, such as mononuclear cells, allogeneic cancer cells, T cells and others, is driving the market. Over 30,000 bone marrow transplants occur every year. The explosive growth of stem cells therapies represents the largest growth opportunity for bone marrow processing systems.Europe and North America spearheaded the market as of 2016, by contributing over 74.0% to the overall revenue. Majority of stem cell transplants are conducted in Europe, and it is one of the major factors contributing to the lucrative share in the cell harvesting system market.

In 2016, North America dominated the research landscape as more than 54.0% of stem cell clinical trials were conducted in this region. The region also accounts for the second largest number of stem cell transplantation, which is further driving the demand for harvesting in the region.Asia Pacific is anticipated to witness lucrative growth over the forecast period, owing to rising incidence of chronic diseases and increasing demand for stem cell transplantation along with stem cell-based therapy.

Japan and China are the biggest markets for harvesting systems in Asia Pacific. Emerging countries such as Mexico, South Korea, and South Africa are also expected to report lucrative growth over the forecast period. Growing investment by government bodies on stem cell-based research and increase in aging population can be attributed to the increasing demand for these therapies in these countries.

Major players operating in the global bone marrow processing systems market are ThermoGenesis (Cesca Therapeutics inc.), RegenMed Systems Inc., MK Alliance Inc., Fresenius Kabi AG, Harvest Technologies (Terumo BCT), Arthrex, Inc. and others

Covid 19 ImpactAnalysis@https://www.trendsmarketresearch.com/report/covid-19-analysis/3184

Read the original post:
Bone Marrow Processing System Market Incisive Insights Regarding Major Regions, Key Players And Opportunities Up To 2025 - Kentucky Journal 24

To Read More: Bone Marrow Processing System Market Incisive Insights Regarding Major Regions, Key Players And Opportunities Up To 2025 – Kentucky Journal 24
categoriaBone Marrow Stem Cells commentoComments Off on Bone Marrow Processing System Market Incisive Insights Regarding Major Regions, Key Players And Opportunities Up To 2025 – Kentucky Journal 24 | dataJune 2nd, 2020
Read All

Stem Cell Therapy Market Analysis and Demand 2017 2025 – Cole of Duty

By daniellenierenberg

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Know the Growth Opportunities in Emerging Markets

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

The regional analysis covers:

Order this Report TOC for Detailed Statistics

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1787<ype=S

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

View post:
Stem Cell Therapy Market Analysis and Demand 2017 2025 - Cole of Duty

To Read More: Stem Cell Therapy Market Analysis and Demand 2017 2025 – Cole of Duty
categoriaBone Marrow Stem Cells commentoComments Off on Stem Cell Therapy Market Analysis and Demand 2017 2025 – Cole of Duty | dataJune 2nd, 2020
Read All

Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron’s Stem Cells | DNA RNA and Cells | News…

By daniellenierenberg

DetailsCategory: DNA RNA and CellsPublished on Monday, 01 June 2020 18:32Hits: 121

The Phase 2 study will assess the safety and efficacy of Longeveron's stem cell treatment under Japan's accelerated regulatory pathway for regenerative medicine.

MIAMI, FL, USA I June 1, 2020 I Longeveron LLC announced today that Japan's Pharmaceutical and Medical Devices Agency (PMDA) (the Japanese agency akin to the United States' Food & Drug Administration) approved a Clinical Trial Notification (CTN) application (akin to an Investigational New Drug Application or "IND" in the US regulatory system), approving the initiation of a Phase 2 clinical trial evaluating the safety and efficacy of Longeveron's Mesenchymal Stem Cells (LMSCs) for the treatment of Aging Frailty in Japanese patients. This is another key milestone for Longeveron's Aging Frailty program, which includes two ongoing Phase 2 clinical trials in the U.S.

"We are extremely pleased to achieve this significant milestone," said Geoff Green, President of Longeveron."This study is designed to determine whether the transplant of donor-derived mesenchymal stem cells can improve healthspan in mild to moderately frail patients, thereby improving functionality and potentially lowering their risk of disability, and dependence on others for care."

Aging Frailty is a common, but reversible, life-threatening geriatric condition affecting millions of Japanese over the age of 65.Frail individuals are vulnerable to adverse health outcomes compared to their age-matched peers despite sharing similar comorbidities and demographics.Clinically, frailty manifests as a combination of symptoms that may include loss of muscle and decreased strength, slowed walking (sarcopenia), lower activity and energy levels, poor endurance, nutritional deficiencies, weight loss and fatigue.Collectively, these lead to overall decline in functionality, and increased risk of disability, dependency, and death.

"The biology of frailty is complex, and includes diminished stem cell activity, reduced ability to repair and regenerate tissue, and immunosenescence (deterioration of the immune system) and chronic systemic inflammation," said Dr. Anthony Oliva, Senior Scientist at Longeveron. "LMSCs have multiple mechanisms of action that can potentially address all of these issues, and thus make them extremely attractive as a therapeutic candidate for the unmet medical need of Aging Frailty."

The planned study is an investigator-initiated, randomized, double-blind, placebo-controlled design,and will be conducted at Juntendo University Hospital (Tokyo) and Japan's National Center for Geriatrics and Gerontology (NCGG) in Nagoya.The study's Principal Investigator, Dr. Hidenori Arai, President of the NCGG, commented that "Japan has one of the oldest and fastest aging societies in the world, with nearly 30% of Japan's citizens over the age of 65.Preventing and reversing functional decline associated with frailty is one of the nation's top priorities, and Longeveron's regenerative medicine approach is an exciting and innovative potential therapeutic option.With the disproportionate infection and mortality rate of older people with COVID-19 and Influenza infection, it is critically important to rapidly test treatments that may be effective."

In Japan, the "Pharmaceutical and Medical Device Act" and the "Act on the Safety of Regenerative Medicine" came into effect in 2014. Under this system, a "Time-limited Conditional Approval" option exists, which allows a manufacturer to conditionally sell regenerative medicine products while proceeding with its Phase 3 clinical trial.

Longeveron's Aging Frailty Research Program

Longeveron sponsors the most extensive and advanced Aging Frailty clinical research program in the world, with more than 200 patients treated with LMSCs worldwide.In the U.S., two clinical trials are currently ongoing:

About LMSCs

Longeveron Allogeneic Mesenchymal Stem Cells (LMSCs) is a regenerative medicine product sourced from the bone marrow of young healthy adult donors.LMSCs are culture expanded under the FDA's current good manufacturing practices (cGMP) to high standards, and maintained as individual "off-the-shelf" doses.

About Longeveron LLC

Longeveron (www.longeveron.com) is a regenerative medicine therapy company founded in 2014. Longeveron's mission is to provide biological solutions for aging-related diseases and life-threatening conditions, and is dedicated to developing safe and effective cell-based therapeutics for unmet medical needs such as Aging Frailty, the Metabolic Syndrome, Alzheimer's Disease, Acute Respiratory Distress Syndrome (ARDS) from COVID-19 infection, and congenital heart defects in children (hypoplastic left heart syndrome).

SOURCE: Longeveron

Read the original post:
Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron's Stem Cells | DNA RNA and Cells | News...

To Read More: Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron’s Stem Cells | DNA RNA and Cells | News…
categoriaBone Marrow Stem Cells commentoComments Off on Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron’s Stem Cells | DNA RNA and Cells | News… | dataJune 1st, 2020
Read All

Stem Cell Assay Market to Witness Growth Acceleration During 2017-2025 – Cole of Duty

By daniellenierenberg

Stem Cell Assay Market: Snapshot

Stem cell assay refers to the procedure of measuring the potency of antineoplastic drugs, on the basis of their capability of retarding the growth of human tumor cells. The assay consists of qualitative or quantitative analysis or testing of affected tissues andtumors, wherein their toxicity, impurity, and other aspects are studied.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=40

With the growing number of successfulstem cell therapytreatment cases, the global market for stem cell assays will gain substantial momentum. A number of research and development projects are lending a hand to the growth of the market. For instance, the University of Washingtons Institute for Stem Cell and Regenerative Medicine (ISCRM) has attempted to manipulate stem cells to heal eye, kidney, and heart injuries. A number of diseases such as Alzheimers, spinal cord injury, Parkinsons, diabetes, stroke, retinal disease, cancer, rheumatoid arthritis, and neurological diseases can be successfully treated via stem cell therapy. Therefore, stem cell assays will exhibit growing demand.

Another key development in the stem cell assay market is the development of innovative stem cell therapies. In April 2017, for instance, the first participant in an innovative clinical trial at the University of Wisconsin School of Medicine and Public Health was successfully treated with stem cell therapy. CardiAMP, the investigational therapy, has been designed to direct a large dose of the patients own bone-marrow cells to the point of cardiac injury, stimulating the natural healing response of the body.

Newer areas of application in medicine are being explored constantly. Consequently, stem cell assays are likely to play a key role in the formulation of treatments of a number of diseases.

Global Stem Cell Assay Market: Overview

The increasing investment in research and development of novel therapeutics owing to the rising incidence of chronic diseases has led to immense growth in the global stem cell assay market. In the next couple of years, the market is expected to spawn into a multi-billion dollar industry as healthcare sector and governments around the world increase their research spending.

The report analyzes the prevalent opportunities for the markets growth and those that companies should capitalize in the near future to strengthen their position in the market. It presents insights into the growth drivers and lists down the major restraints. Additionally, the report gauges the effect of Porters five forces on the overall stem cell assay market.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=40<ype=S

Global Stem Cell Assay Market: Key Market Segments

For the purpose of the study, the report segments the global stem cell assay market based on various parameters. For instance, in terms of assay type, the market can be segmented into isolation and purification, viability, cell identification, differentiation, proliferation, apoptosis, and function. By kit, the market can be bifurcated into human embryonic stem cell kits and adult stem cell kits. Based on instruments, flow cytometer, cell imaging systems, automated cell counter, and micro electrode arrays could be the key market segments.

In terms of application, the market can be segmented into drug discovery and development, clinical research, and regenerative medicine and therapy. The growth witnessed across the aforementioned application segments will be influenced by the increasing incidence of chronic ailments which will translate into the rising demand for regenerative medicines. Finally, based on end users, research institutes and industry research constitute the key market segments.

The report includes a detailed assessment of the various factors influencing the markets expansion across its key segments. The ones holding the most lucrative prospects are analyzed, and the factors restraining its trajectory across key segments are also discussed at length.

Global Stem Cell Assay Market: Regional Analysis

Regionally, the market is expected to witness heightened demand in the developed countries across Europe and North America. The increasing incidence of chronic ailments and the subsequently expanding patient population are the chief drivers of the stem cell assay market in North America. Besides this, the market is also expected to witness lucrative opportunities in Asia Pacific and Rest of the World.

Global Stem Cell Assay Market: Vendor Landscape

A major inclusion in the report is the detailed assessment of the markets vendor landscape. For the purpose of the study the report therefore profiles some of the leading players having influence on the overall market dynamics. It also conducts SWOT analysis to study the strengths and weaknesses of the companies profiled and identify threats and opportunities that these enterprises are forecast to witness over the course of the reports forecast period.

Some of the most prominent enterprises operating in the global stem cell assay market are Bio-Rad Laboratories, Inc (U.S.), Thermo Fisher Scientific Inc. (U.S.), GE Healthcare (U.K.), Hemogenix Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), STEMCELL Technologies Inc. (CA), Cell Biolabs, Inc. (U.S.), and Cellular Dynamics International, Inc. (U.S.).

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=40

About Us:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read this article:
Stem Cell Assay Market to Witness Growth Acceleration During 2017-2025 - Cole of Duty

To Read More: Stem Cell Assay Market to Witness Growth Acceleration During 2017-2025 – Cole of Duty
categoriaCardiac Stem Cells commentoComments Off on Stem Cell Assay Market to Witness Growth Acceleration During 2017-2025 – Cole of Duty | dataJune 1st, 2020
Read All

The 15 Best New Products to Try in Isolation This Month – InStyle

By daniellenierenberg

My summer countdown usually starts on the first day of fall. However, with social distancing still in place and travel completely off the cards for the foreseeable future, it's tough to get excited about what's arguably the best time of year.

Throughout quarantine, beauty products have given me a little bit of comfort and madethe stressand challenges of our current reality seem more manageable.

But even though everyone'sdaily routines have changed and the beauty industry has been greatly impacted by COVID-19, brands haven't stopped launching new products.

RELATED:Shopping for Makeup Post COVID-19 Lockdown Will Never Be the Same

This month's just-launched and soon-to-launch makeup, skincare, and haircare products include a number of treatments that are perfect for taking a time out and indulging in a little TLC in isolation. Briogeo's repairing hair mask, HoliFrog's glow-boosting cleanser, and Gucci Westman'svelvety eyeshadows are just a few examples.

Ahead, 15 new beauty products to give yourself some extra self-care while stuck at home.

See more here:
The 15 Best New Products to Try in Isolation This Month - InStyle

To Read More: The 15 Best New Products to Try in Isolation This Month – InStyle
categoriaSkin Stem Cells commentoComments Off on The 15 Best New Products to Try in Isolation This Month – InStyle | dataJune 1st, 2020
Read All

Genetic features pave way for targeted BPDCN therapies – Dermatology Times

By daniellenierenberg

Researchers are learning more about genetic aberrations common in the rare but clinically aggressive hematological cancer blastic plasmacytoid dendritic cell neoplasm. There is one targeted therapy approved by the U.S. Food and Drug Administration: Elzonris (tagraxofusp-erzs, Stemline). However, more treatment options are needed to improve the cancers clinical outcome, according to a review published May 2020 in Critical Reviews Oncology/Hematology.1

Dermatologists might be the first providers to encounter patients with blastic plasmacytoid dendritic cell neoplasm because more than 70% of these patients have cutaneous lesions. Those lesions often are asymptomatic and vary in size. The skin lesions tend to have nodules, plaques or bruise-like areas, a brown to violet color and might be solitary or multifocal, according to the authors.

Blastic plasmacytoid dendritic cell neoplasm often originates from type 2 myeloid-derived resting plasmacytoid dendritic cell precursors. Recent research suggests providers can diagnose the cancer when patients express at least four of five plasmacytoid dendritic cell specific markers, CD4, CD56, CD123, TCL1 and BDCA-2, without expressing myeloid, T-cell or B-cell lineage markers.

Commonly, [blastic plasmacytoid dendritic cell neoplasm] is characterized by high CD123 expression, aberrant NF-B [nuclear factor-B] activation, dependence on TCF4-/BRD4-network, and deregulated cholesterol metabolism, they wrote.

Despite advancing knowledge about the cancer type, patients median overall survival remains at 12 to 14 months, according to the paper. Conventional treatment approaches include chemotherapy, radiotherapy and ultimately hematopoietic stem cell transplantation. The challenges with conventional therapies are while blastic plasmacytoid dendritic cell neoplasm is sensitive to some chemotherapy regimens, patient relapse is high at more than 60%. And many patients with blastic plasmacytoid dendritic cell neoplasm are too old or frail to have intensive chemotherapy or hematopoietic stem cell transplantation, according to the authors.

Recently, the most attractive agent for [blastic plasmacytoid dendritic cell neoplasm] is tagraxofusp, which is composed of the catalytic and translocation domains of diphtheria toxin (DT) fused to interleukin-3 (IL-3), the authors wrote.

Blastic plasmacytoid dendritic cell neoplasm cells overexpress interleukin-3 receptor subunit alpha (IL3RA, also called CD123). Elzonris, or tagraxofusp-erzs, is a CD123-directed cytotoxin given intravenously, which is used to treat blastic plasmacytoid dendritic cell neoplasm in adults and in pediatric patients 2 years and older.

Researchers reported in a study of 47 blastic plasmacytoid dendritic cell neoplasm patients published in 2019 in the New England Journal of Medicine that tagraxofusp led to clinical responses in untreated and relapsed patients.2 The overall response rate with tagraxofusp was 90% and the primary outcome of complete response and clinical complete response was 72% among the previously untreated patients. Overall response was 67% in the previously treated patients. Serious adverse events including capillary leak syndrome, hepatic dysfunction and thrombocytopenia were common, according to the NEJM paper.

More targeted therapies are needed to treat blastic plasmacytoid dendritic cell neoplasm, but many potential therapeutic agents are not advancing to clinical trials, according to authors of the paper in Critical Reviews Oncology/Hematology.

Common blastic plasmacytoid dendritic cell neoplasm characteristics are genetically heterogeneous and provide valuable drug targets, according to the authors.

Apart from aberrant activation of NF-B signaling pathway, which is highly dependent on TCF4- and BRD4- transcriptional networks, cholesterol metabolism deregulation and CD123 expression, defects of DNA damage repair and mitosis are new, potential common features of the cancer. Corresponding therapies might be promising, the authors wrote.

Venetoclax, anti-CD123 CAR-T, XmAb14045 and IMGN632 are in clinical trials for blastic plasmacytoid dendritic cell neoplasm. But the authors noted that bortezomib, lenalidomide, 5-aza and pralatrexate could easily be pushed to the front line of the cancers treatment.

Disclosures:

The authors report no relevant disclosures.

References:

1. Zhang X, Sun J, Yang M, Wang L, Jin J. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm. Crit Rev Oncol Hematol. 2020 May;149:102928.2. Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019;380(17):1628-1637.

Go here to see the original:
Genetic features pave way for targeted BPDCN therapies - Dermatology Times

To Read More: Genetic features pave way for targeted BPDCN therapies – Dermatology Times
categoriaSkin Stem Cells commentoComments Off on Genetic features pave way for targeted BPDCN therapies – Dermatology Times | dataJune 1st, 2020
Read All

Regenerative Therapies: Helping Horses Self-Heal The Horse – TheHorse.com

By daniellenierenberg

The art (and existing science) of regenerative medicine in equine practice, and whats to come

Regenerative therapy is an umbrellaterm encompassing any method that encourages the body to self- heal. Because it is drawing onits own properties, healing tissue more closely resembles native tissue than weak, disorganized scar tissue typically seen post-injury.

The goal is to allow restoration of normal function and structure of the injured tissue to allow horses to perform at their previous level, whatever that might be, with a reduced risk of reinjury, says Kyla Ortved, DVM, PhD, Dipl. ACVS, ACVSMR, assistant professor of large animal surgery at the University of Pennsylvanias New Bolton Center, in Kennett Square.

She says the three main components of regenerative medicine that help tissues self-heal include:

A specific therapy may incorporate some or all three of these components, says Ortved.

Due to the regenerative therapy industrys popularity and continued growth, many articles weve published review recent laboratory studies about stem cell production and data on efficacy andsafety (you can find them at TheHorse.com/topics/regenerative-medicine). Here, well review the basics of three regenerative modalities commonly used in equine medicine and when veterinarians and horse owners might consider each.

With this approach the practitioner collects blood from a horse and processes it using a commercial system that concentrates the platelets. When he or she injects that concentrated platelet product back into the horse, granules within the platelets release an array of growth factors that aim to facilitate and modulate the healing process. Specifically, granule-derived growth factors encourage target tissue cells at the injury site to migrate and proliferate, improve extracellular matrix synthesis, and stimulate blood vessel development.

Recently, leukocyte-reduced PRP hasbecome many equine veterinarians PRP product of choice. These preparations contain fewer white blood cells (leukocytes) and, reportedly, inflammatory mediators than normal PRP products do. These mediators break tissues down, effectively counteracting the anabolic (tissue-building) effects of the platelets and their granules.

Veterinarians can easily prepare ACS by collecting a blood sample from the patient, then incubating it with special commercially available glass beads to stimulate interleukin-1 receptor antago- nist protein (IRAP) production. Theythen inject the resultant IRAP-rich serumsample back into the patient at the target location or injury site. This protein blocks the action of interleukin-1, a powerful and damaging pro-inflammatory mediator. Additionally, glass bead incubation stimulates the production of anti-inflammatory mediators and growth factors similar to those found in PRP.

Ortved says its important to remember that all biologics, including PRP and IRAP, contain various concentrations of growth factors and bioactive protein.

Remember, they are made from your horses blood and, therefore, containall of the components in blood, just in varying concentrations, she says.

Regenerative therapies that contain highconcentrations of IRAP include IRAP II, autologous protein solution (APS), and bone marrow aspirate concentrate (BMAC).

In certain tissues, such as adipose (fat) and bone marrow, we can find specific cells that have the ability to self-renew and grow more than 200 types of body cells. Veterinarians can isolate these cells, called stem cells or progenitor cells, and either:

Perhaps more important than theirability to differentiate into other celltypes, stem cells have powerful anti-inflammatoryproperties and play acentral role in coordinating healing in alltypes of tissues through cell-to-cell signaling,Ortved says.

Which of these three modality typeswill provide the most benefit to yourhorse depends on a variety of factors thatyou and your veterinarian will consider.

Read the original:
Regenerative Therapies: Helping Horses Self-Heal The Horse - TheHorse.com

To Read More: Regenerative Therapies: Helping Horses Self-Heal The Horse – TheHorse.com
categoriaBone Marrow Stem Cells commentoComments Off on Regenerative Therapies: Helping Horses Self-Heal The Horse – TheHorse.com | dataMay 31st, 2020
Read All

Page 21234..1020..»